Loading cancer entity…
Loading cancer entity…
Clinical trials
805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05822817 | Comparison of Postoperative Recovery of Sevoflurane and Propofol After Transsphenoidal Surgery | completed | Phase 4 | 252 | Peking Union Medical College HospitalOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT03289741 | A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide | completed | Phase 4 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 9, 2025 |
| clinicaltrials |
| NCT02842749 | Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China | completed | Phase 4 | 61 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT04524442 | Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients | completed | Phase 4 | 42 | Advanced Accelerator ApplicationsINDUSTRY | 4 | Jan 24, 2025 | clinicaltrials |
| NCT01794793 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | completed | Phase 4 | 337 | RECORDATI GROUPINDUSTRY | 28 | Oct 1, 2024 | clinicaltrials |
| NCT02075606 | Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients(CALM-NET) | completed | Phase 4 | 50 | IpsenINDUSTRY | 1 | Jun 7, 2019 | clinicaltrials |
| NCT01371643 | Surgical Debulking of Pituitary Adenomas | completed | Phase 4 | 41 | NYU Langone HealthOTHER | 1 | Aug 29, 2016 | clinicaltrials |
| NCT01317615 | RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation | completed | Phase 4 | 49 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 30, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Jun 8, 2025source: clinicaltrials